Program
cobimetinib
Also written as “Cobimetinib”, “HM95573, cobimetinib” and “GDC-0973 IV Infusion”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasms · Ovarian Neoplasms, led by 2 companies.
Drug pageCobimetinib: every studyAll 94 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 364 open or running | phase 3since Sep 18, 2012 | Apr 18, 2007 | Nov 30, 2026phase 2 · NCT04302025 |
| Hanmi Pharmaceutical | 22 open or running | phase 2since Feb 27, 2026 | Aug 7, 2017 | Sep 2029phase 2 · NCT07449754 |
Also a collaborator on its studies: Halozyme Therapeutics and BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hanmi Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2017First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03284502 · 148 enrolled · Korea, Republic of
- Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedNCT07449754 · 45 planned · South Korea
Ahead
- Sep 2029Primary completion: phase 2 study in MelanomaNCT07449754
TargetBeta
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 2 Hanmi Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07449754Melanoma · South Korea | 2 | Recruiting | Sep 2029 | 45 |
| NCT03284502Neoplasm Metastasis · Korea, Republic of | 1 | Active, not recruiting | Sep 30, 2024 | 148 |
How it is read
Names in the registry
- “Cobimetinib”, 34 entries
- “cobimetinib”, 4 entries
- “HM95573, cobimetinib”, 2 entries
- “GDC-0973 IV Infusion”, 1 entry
- “GDC-0973 Oral Capsules”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 7 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colorectal Neoplasms, 3 studies
- Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.